IL131815A0 - Methods and compositions for modulating responsiveness to corticosteroids - Google Patents

Methods and compositions for modulating responsiveness to corticosteroids

Info

Publication number
IL131815A0
IL131815A0 IL13181598A IL13181598A IL131815A0 IL 131815 A0 IL131815 A0 IL 131815A0 IL 13181598 A IL13181598 A IL 13181598A IL 13181598 A IL13181598 A IL 13181598A IL 131815 A0 IL131815 A0 IL 131815A0
Authority
IL
Israel
Prior art keywords
corticosteroids
compositions
methods
modulating responsiveness
responsiveness
Prior art date
Application number
IL13181598A
Other languages
English (en)
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/820,692 external-priority patent/US6054487A/en
Application filed by Basf Ag filed Critical Basf Ag
Publication of IL131815A0 publication Critical patent/IL131815A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13181598A 1997-03-18 1998-03-12 Methods and compositions for modulating responsiveness to corticosteroids IL131815A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/820,692 US6054487A (en) 1997-03-18 1997-03-18 Methods and compositions for modulating responsiveness to corticosteroids
US1634698A 1998-01-30 1998-01-30
PCT/US1998/004916 WO1998041232A2 (en) 1997-03-18 1998-03-12 Compositions for modulating responsiveness to corticosteroids

Publications (1)

Publication Number Publication Date
IL131815A0 true IL131815A0 (en) 2001-03-19

Family

ID=26688484

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13181598A IL131815A0 (en) 1997-03-18 1998-03-12 Methods and compositions for modulating responsiveness to corticosteroids

Country Status (20)

Country Link
EP (1) EP0998300A1 (bg)
JP (1) JP2002504091A (bg)
KR (1) KR20000076420A (bg)
CN (1) CN1269722A (bg)
AU (1) AU734756B2 (bg)
BG (1) BG103808A (bg)
BR (1) BR9810409A (bg)
CA (1) CA2282845A1 (bg)
DE (1) DE998300T1 (bg)
ES (1) ES2146192T1 (bg)
HU (1) HUP0104439A3 (bg)
ID (1) ID22975A (bg)
IL (1) IL131815A0 (bg)
NO (1) NO994506L (bg)
NZ (1) NZ337769A (bg)
PL (1) PL336464A1 (bg)
SI (1) SI20110A (bg)
SK (1) SK122199A3 (bg)
TR (1) TR199902615T2 (bg)
WO (1) WO1998041232A2 (bg)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6706264B1 (en) 1994-03-14 2004-03-16 Genetics Institute, Llc Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y
ZA95960B (en) * 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
US7220717B2 (en) 1997-08-14 2007-05-22 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
US7704944B2 (en) 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
US6184210B1 (en) 1997-10-10 2001-02-06 Cytovia, Inc. Dipeptide apoptosis inhibitors and the use thereof
AR015966A1 (es) * 1997-10-17 2001-05-30 Smithkline Beecham Corp Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
EP1516630A3 (en) * 1997-10-31 2006-05-03 Wyeth Use of anti-il-12 antibodies in transplantation rejection
EP0969867B1 (en) * 1997-10-31 2004-09-01 Wyeth Use of anti-il-12 antibodies in transplantation rejection
WO1999025737A1 (en) * 1997-11-19 1999-05-27 Tanox Pharma B.V. Compositions and methods for treatment of autoimmune diseases, using a monoclonal antibody to the interleukin-12 beta2-chain
CN1297354A (zh) * 1998-03-16 2001-05-30 西托维亚公司 二肽卡斯帕酶抑制剂及其用途
CA2355345A1 (en) * 1998-11-27 2001-06-28 Technion Research & Development Foundation Ltd. Interferon gamma inducing factor based vaccine and use of same for protective immunity against multiple sclerosis
AU1843200A (en) * 1998-12-09 2000-06-26 Protein Design Labs, Inc. Animal model for psoriasis for the prevention and treatment of psoriasis in humans
DE60030097T2 (de) 1999-03-16 2007-03-08 Cytovia, Inc., San Diego Substituierte 2-aminobenzamin caspase inhibitoren und ihre verwendung
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
DE19915465A1 (de) * 1999-04-06 2000-10-19 Apotech Res & Dev Ltd Verwendung eines Caspase-Inhibitors zur Proliferationshemmung von Zellen und Verwendung eines oder mehrerer Caspase-Inhibitors/en zur Behandlung von Erkrankungen beruhend auf Lymphozyten-Hyperproliferation oder zur Suppression einer Immunantwort durch Lymphozyten
KR20020005665A (ko) 1999-04-09 2002-01-17 추후보정 카스파제 저해제 및 그것의 용도
IL131047A0 (en) 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
MXPA02002038A (es) 1999-08-27 2002-10-31 Cytovia Inc Acidos alfa-hidroxi substituidores inhibidores de la caspasa y uso de los mismos.
WO2001019373A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6566338B1 (en) 1999-10-12 2003-05-20 Cytovia, Inc. Caspase inhibitors for the treatment and prevention of chemotherapy and radiation therapy induced cell death
TWI373343B (en) 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
ATE332708T1 (de) * 2000-06-06 2006-08-15 Glaxo Group Ltd Krebsbehandlung zusammensetzung, welche ein antineoplastisches mittel und pde4 inhibitor enthält
WO2001097815A2 (de) * 2000-06-22 2001-12-27 Willy Ben Moussa Ben Mohammed Verwendung von glukokortikosteroiden zur herstellung eines medikamentes für die behandlung von haarschwund
US20020025317A1 (en) * 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
WO2002022127A1 (en) * 2000-09-13 2002-03-21 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
EP1199074A1 (en) * 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
EP1188438A1 (en) * 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EA010180B1 (ru) * 2001-01-29 2008-06-30 Лаборатуар Сероно Са Применение ингибитора il-18 для приготовления лекарственного средства для лечения и/или профилактики кардиомиопатии
ES2334773T3 (es) * 2001-05-16 2010-03-16 Yeda Research And Development Co. Ltd. Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis.
PT2087908T (pt) 2001-06-26 2018-07-16 Amgen Inc Anticorpos contra opgl
RU2322984C2 (ru) * 2001-10-05 2008-04-27 Комбинаторкс, Инкорпорейтед Комбинации для лечения иммуновоспалительных расстройств
JP2003342196A (ja) * 2002-05-31 2003-12-03 Mukku:Kk 静脈注射用組成物、その製造法およびその製剤
BR0314713A (pt) * 2002-09-24 2005-07-26 Combinatorx Inc Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias
WO2004028545A1 (en) * 2002-09-25 2004-04-08 Astrazeneca Ab A COMBINATION OF A LONG-ACTING β2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
CA2566877A1 (en) * 2004-05-17 2005-11-24 Keio University Medicinal composition and therapeutic method
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
NZ553166A (en) * 2004-07-16 2010-02-26 Atsuo Sekiyama IL-18 receptor antagonist and pharmaceutical composition containing the antagonist
CA2584169A1 (en) * 2004-10-13 2006-04-20 Kyowa Hakko Kogyo Co., Ltd. Remedies/preventives for chronic skin disease
AU2006270165B2 (en) 2005-07-14 2010-03-11 Neothetics, Inc. Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
CN104524567A (zh) 2007-01-16 2015-04-22 阿布维公司 用于治疗银屑病的方法
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
TW201513883A (zh) 2008-03-18 2015-04-16 Abbvie Inc 治療牛皮癬的方法
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
SG190878A1 (en) 2010-11-24 2013-07-31 Lithera Inc Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2015063669A1 (en) 2013-10-30 2015-05-07 Wockhardt Limited Pharmaceutical compositions comprising combination of roflumilast and acebrophylline or pharmaceutically acceptable salts thereof
IL311534A (en) * 2021-09-22 2024-05-01 Iolyx Therapeutics Inc Methods for treating ocular inflammatory diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
JP3042866B2 (ja) * 1989-09-08 2000-05-22 グラクソ・グループ・リミテッド 呼吸疾患治療薬
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
MX9304585A (es) * 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
GB9426252D0 (en) * 1994-12-24 1995-02-22 Glaxo Group Ltd Pharmaceutical composition
NZ306281A (en) * 1995-04-14 1999-07-29 Glaxo Wellcome Inc Metered dose inhaler with part or all internal surfaces coated with fluorocarbon polymers for dispensing beclomethasone dipropionate

Also Published As

Publication number Publication date
ES2146192T1 (es) 2000-08-01
BR9810409A (pt) 2000-08-22
JP2002504091A (ja) 2002-02-05
NZ337769A (en) 2002-09-27
HUP0104439A2 (hu) 2002-04-29
SK122199A3 (en) 2000-12-11
NO994506L (no) 1999-11-17
AU734756B2 (en) 2001-06-21
CA2282845A1 (en) 1998-09-24
DE998300T1 (de) 2001-03-01
SI20110A (sl) 2000-06-30
AU6760498A (en) 1998-10-12
KR20000076420A (ko) 2000-12-26
BG103808A (bg) 2000-07-31
EP0998300A1 (en) 2000-05-10
HUP0104439A3 (en) 2002-08-28
ID22975A (id) 1999-12-23
PL336464A1 (en) 2000-06-19
WO1998041232A2 (en) 1998-09-24
CN1269722A (zh) 2000-10-11
TR199902615T2 (xx) 2000-03-21
WO1998041232A3 (en) 2000-10-05
NO994506D0 (no) 1999-09-17

Similar Documents

Publication Publication Date Title
IL131815A0 (en) Methods and compositions for modulating responsiveness to corticosteroids
AU9214398A (en) Compositions and methods for treating water
EP0960019A4 (en) METHOD FOR PRODUCING REPLICAS AND COMPOSITIONS USED THEREFOR
PL335168A1 (en) Compositions for and methods of reducing intracocular hypertension
ZA9810217B (en) New composition of matter
EP0975371A4 (en) ANTISENSE OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR MODULATING THE ACTIVATING PROTEIN 1.
PL322494A1 (en) Compounds and compositions intended to provide active substances
AU7127600A (en) Methods and compositions for modulating responsiveness to corticosteroids
AU4196196A (en) Methods and compositions relating to plant delta6 palmitoyl-acyl carrier protein desaturase
PL320487A1 (en) Haemorrhoidal compositions and method of applying them
ZA984127B (en) New composition of matter
AU3671099A (en) Methods and compositions pertaining to pd-loops
EG23808A (en) Microencapsulated composition
IL132169A0 (en) Method and composition for modulating amyloidosis
ZA989399B (en) Method and composition
ZA9710419B (en) Compositions and methods for regulating apoptosis
GB9601978D0 (en) Application of materials to substrates
MX210074B (en) Coating compositions for development electrodes and methods thereof
GB9624501D0 (en) Insecticial compositions and method
EP0928419A4 (en) COMPOSITIONS AND METHODS FOR REGULATING THE EXPRESSION OF THE TYPE-I INTERLEUKIN-1 RECEPTOR
IL113438A0 (en) Compositions and methods for cell transformation
AU4981199A (en) Compositions and methods for modulating sexual activity
AU7358098A (en) Radioisotope concentrator methods and compositions
AU2556195A (en) CD40 binding compositions and methods of using same
AUPO982097A0 (en) Methods and compositions for use therein